Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcel Kool

Showing results (91-100 of 337) with videos related to

Pageof 34
Sort By:
Acta Neuropathologica Communications|March 2, 2016
Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profilesAnnett Hölsken, Martin Sill, Jessica Merkle, et al.
Neuro-Oncology|February 16, 2021
Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicatorAndrey Korshunov, Konstantin Okonechnikov, Damian Stichel, et al.
Journal of Neuro-Oncology|October 12, 2012
HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatmentTill Milde, Marco Lodrini, Larissa Savelyeva, et al.
Brain Pathology (Zurich, Switzerland)|May 3, 2021
Histopathological patterns in atypical teratoid/rhabdoid tumors are related to molecular subgroupFrancesca Zin, Jennifer A Cotter, Christine Haberler, et al.
Scientific Reports|April 19, 2017
Establishment and characterization of an orthotopic patient-derived Group 3 medulloblastoma model for preclinical drug evaluationEmma Sandén, Cecilia Dyberg, Cecilia Krona, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2021
FOXR2 Stabilizes MYCN Protein and Identifies Non-<i>MYCN</i>-Amplified Neuroblastoma Patients With Unfavorable OutcomeFelix Schmitt-Hoffner, Sjoerd van Rijn, Umut H Toprak, et al.
Neuro-Oncology Advances|April 27, 2022
Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastomaSonja Krausert, Sebastian Brabetz, Norman L Mack, et al.
Acta Neuropathologica|April 29, 2019
Molecular progression of SHH-activated medulloblastomasAndrey Korshunov, Konstantin Okonechnikov, Felix Sahm, et al.
Neuro-Oncology|September 26, 2018
DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomasAndrey Korshunov, Felix Sahm, Olga Zheludkova, et al.
Journal of Neuropathology and Experimental Neurology|February 8, 2006
OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomasTalitha de Haas, Esmeralda Oussoren, Wieslawa Grajkowska, et al.
Pageof 34

Showing results (91-100 of 337) with videos related to

Sort By:
Pageof 34
Acta Neuropathologica Communications|March 2, 2016
Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profilesAnnett Hölsken, Martin Sill, Jessica Merkle, et al.
Neuro-Oncology|February 16, 2021
Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicatorAndrey Korshunov, Konstantin Okonechnikov, Damian Stichel, et al.
Journal of Neuro-Oncology|October 12, 2012
HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatmentTill Milde, Marco Lodrini, Larissa Savelyeva, et al.
Brain Pathology (Zurich, Switzerland)|May 3, 2021
Histopathological patterns in atypical teratoid/rhabdoid tumors are related to molecular subgroupFrancesca Zin, Jennifer A Cotter, Christine Haberler, et al.
Scientific Reports|April 19, 2017
Establishment and characterization of an orthotopic patient-derived Group 3 medulloblastoma model for preclinical drug evaluationEmma Sandén, Cecilia Dyberg, Cecilia Krona, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2021
FOXR2 Stabilizes MYCN Protein and Identifies Non-<i>MYCN</i>-Amplified Neuroblastoma Patients With Unfavorable OutcomeFelix Schmitt-Hoffner, Sjoerd van Rijn, Umut H Toprak, et al.
Neuro-Oncology Advances|April 27, 2022
Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastomaSonja Krausert, Sebastian Brabetz, Norman L Mack, et al.
Acta Neuropathologica|April 29, 2019
Molecular progression of SHH-activated medulloblastomasAndrey Korshunov, Konstantin Okonechnikov, Felix Sahm, et al.
Neuro-Oncology|September 26, 2018
DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomasAndrey Korshunov, Felix Sahm, Olga Zheludkova, et al.
Journal of Neuropathology and Experimental Neurology|February 8, 2006
OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomasTalitha de Haas, Esmeralda Oussoren, Wieslawa Grajkowska, et al.
Pageof 34